Treatment of acquired aplastic anemia

Haematologica

Volumn 92, Issue 1, 2007, Pages 2-5

  Marsh, Judith C W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ANTIBIOTIC PROPHYLAXIS; APLASTIC ANEMIA; BONE MARROW DEPRESSION; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; DYSKERATOSIS CONGENITA; EDITORIAL; FANCONI ANEMIA; FEVER; GENE MUTATION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MIXED MYELODYSPLASTIC MYELOPROLIFERATIVE DISEASE; PANCYTOPENIA; PNEUMONIA; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; BONE MARROW; CHILD; CLINICAL TRIALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME;

EID: 33846925063     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11107     Document Type: Editorial

References (44)

1. British Committee for Standards in Haematology (BCSH) General Haematology Task Force. Guidelines for the diagnosis and management of acquired aplastic anaemia. Br J Haematol 2003;123:782-801.
2. Yamasuchi H, Calado RT, Ly H, Kajigaya S, Baerlocher GM, Chanock SJ, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 2005; 352:1413-22.
3. Vulliamy T, Marrone A, Szydlo R, Walne A, Mason PJ, Dokal I. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Gen 2004;36:447-9.
4. Mikhailova N, Sessarego M, Fugazza G, Caimo A, De Filippi S, van Lint MT, et al. Cytogenetic abnormalities in patients with severe aplastic anemia. Haematologica 1996;81:418-22.
5. Gupta V, Brooker C, Tooze J, Qi-long Y, Sage D, Turner D, et al. Clinical relevance of cytogenetic abnormalities at diagnosis of acquired aplastic anaemia in adults. Br J Haematol 2006; 134:95-9.
6. Marsh JC, Socie G, Schrezenmeier H, Tichelli A, Gluckman E, Ljungman P, et al. Haemopoietic growth factors in aplastic anaemia: a cautionary note. European Bone Marrow Transplant Working Party for Severe Aplastic Anaemia. Lancet 1994;344: 172-3.
7. Passweg JR, Socie G, Hinterberger W, Bacigalupo A, Biggs JC, Camitta BM, et al. Bone marrow transplantation for severe aplastic anemia: has outcome improved? Blood 1997; 90:858-64.
8. Ades L, Mary JY, Robin M, Ferry C, Porcher R, Esperou H, et al. Long-term outcome after bone marrow transplantation for severe aplastic anaemia. Blood 2004;103:2490-7.
9. Kobayashi R, Yabe H, Hara J, Morimoto A, Tsichida M, Mugishima H, et al. Preceeding immunosuppressive therapy with antithymocyte globulin and ciclosporin increases the incidence of graft rejection in children with aplastic anaemia who underwent allogeneic bone marrow transplantation from HLA-identical siblings. Br J Haematol 2006;135:693-6.
10. Kahl C, Leisenring W, Deeg HJ, Chauncey TR, Flowers ME, Martin PJ, et al. Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long term follow up. Br J Haematol 2005;130:747-51.
11. Locasciulli, A, Oneto R, Bacigalupo A, Socie G, Korthof E, Bekassy A, et al. Outcome of patients with acquired aplastic anaemia given first line bone marrow transplantation or immunosuppression treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2007; 92:10-7.
12. Bacigalupo A, Brand R, Oneto R, Bruno B, Socie G, Passweg J, et al. Treatment of acquired severe aplastic anemia: Bone marrow transplantation compared with immunosuppressive therapy - The European Group for Blood and Marrow Transplantation experience. Semin Hematol 2000; 37: 69-80.
13. Deeg HJ, Leisenring W, Storb R, Nims J, Flowers ME, Witherspoon RP, et al. Long term outcome after marrow transplantation for severe aplastic anemia. Blood 1998; 91:3637-45.
14. Schrezenmeier H, Bredeson C, Bruno B, Loberiza FR, Camitta B, Oneto R, et al. Comparison of allogeneic bone marrow and peripheral blood stem cell transplantation for aplastic anaemia: collaborative study of European Blood and Marrow Transplant Group (EBMT) and International Bone Marrow Transplant Registry (IBMTR). Blood 2003; 267a[abstract].
15. Champlin RE, Perez WS, Passweg J, Klein JP, Camitta BM, Gluckman E, et al. Addition of antithymocyte globulin (ATG) to cyclophosphamide (Cy) for HLA-identical sibling allogeneic bone marrow transplantation (BMT) for severe aplastic anaemia (SAA): results of a randomized controlled trial. Blood 2003;269a[abstract].
16. Gupta V, Ball S, Yi Q, Sage D, McCann S, Lawler M, et al. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia. Biol. Blood Marrow Transplant 2004;7:39-44.
17. Stem M, Passweg J, Locasciulli A, Socie G, Schrezenemeir H, Bekassy A, et al. Influence of donor/recipient sex matching on outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia. Transplant 2006; 82:218-26.
18. Huss R, Deeg HJ, Gooley T, Bryant E, Leisenring W, Clift R, et al. Effect of mixed chimerism on graft versus host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anaemia or chronic myeloid leukaemia. Bone Marrow Transplant 1996;18: 767-76.
19. McCann S, Passweg J, Bacigalupo A, Locasciulli A, Ryan J, Schrezenemeir D, et al. The influence of cyclosporin alone, or cyclosporin and methotrexate on the incidence of mixed haematopoietic chimaerism following allogeneic sibling bone marrow transplantation for severe aplastic anaemia. Bone Marrow Transplant 2006;in press.
20. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. The German Aplastic Anemia Study Group. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003;101:1236-42.
21. Schrezenmeier H, Marin P, Raghavachar A, McCann S, Hows J, Gluckman E, et al. Relapse of aplastic anaemia after immunosuppressive treatment: a report from the European Bone Marrow Transplantation Group SAA Working Party. Br J Haematol 1993;85:371-7.
22. Socie G, Rosenfeld S, Frickhofen N, Gluckman E, Tichelli A. Late clonal diseases of treated aplastic anemia. Semin Hematol 2000;37:91-101.
23. Gluckman E, Rokicka-Milewska R, Hann I, Nikiforakis E, Tavakoli F, Cohen-Scali S, et al. and the European Group for Blood and Marrow Transplantation Working Party for Severe Aplastic Anaemia. Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br J Haematol 2002; 119:1075-82.
24. Kojima S, Ohara A, Tsuchida M, Kudoh T, Hanada R, Okimoto Y, et al. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood 2002;100:786-90.
25. Locasciulli A, Arcese W, Locatelli F, Di Bona E, Bacigalupo A. Treatment of aplastic anaemia with granulocyte-colony stimulating factor and risk of malignancy. Lancet 2001;357:43-4.
26. Socie G, Mary JY, Schrezenemeir H, Marsh J, Bacigalupo A, Locasciulli A, et al. Granulocyte-stimulating factor and severe aplastic anaemia: a survey by the European Group for Blood and Marrow transplantation (EBMT). Blood 2006;[Epub ahead of print].
27. Tichelli A, Passweg J, Nissen C, Bargetzi M, Hoffmann T, Filipowicz A, et al. Repeated treatment with horse anti-lymphocyte globulin for severe aplastic anaemia. Br J Haematol 1998;100:393-400.
28. Scheinberg P, Nunez O, Young R. Re-treatment with rabbit antithymocyte globulin and cyclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol 2006;133:622-27.
29. Di Bona E, Rodeghiero F, Bruno B, Gabbas A, Foa P, Locasciulli A, et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course or intensive immunosuppressive therapy. Br J Haematol 1999;107:330-4.
30. Gupta V, Gordon-Smith E, Cook G, Parker A, Duguid J, Wilson K, et al. A third course of anti-thymocyte globulin in aplastic anaemia is only beneficial in previous responders. Br J Haematol 2005;128:110-7.
31. Marsh J, Schrezenmeier H, Marin P, Ilhan O, Ljungman P, McCann S, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anaemia: a report from the European blood and marrow transplant (EBMT) severe aplastic anaemia working party. Blood 1999;93:2191-5.
32. Passweg J, Perez W, Eapen M, Camitta B, Gluckman E, Hinterberger W, et al. Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia. Bone Marrow Transplant 2006;37:641-9.
33. Deeg H, O'Donnell M, Tolar J, Agarwal R, Harris R, Feig S, et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood 2006;108;1485-91.
34. Bacigalupo A, Locatelli F, Lanino E, Marsh J, Socie G, Maury S, et al. Fludarabine, cyclophosphamide and ATG for alternative donor transplants in acquired severe aplastic anaemia - a report of the EBMT SAA Working Party. Bone Marrow Transplant 2005;36:947-50.
35. Gupta V, Ball S, Sage D, Ortin M, Freires M, Gordon-Smith T, et al. Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning. Bone Marrow Transplant 2005;35:467-71.
36. Maury S, Balere-Appert M, Chir Z, Boiron J, Galambrun C, Yakouben K, et al. Unrelated stem cell transplantation for severe acquired aplastic anaemia: improved outcome at the era of "high-resolution" HLA matching between donor and recipient. Haematologica [submitted].
37. Schrezenmeier H, Bacigalupo A, Donner H, Ramenghi A, Locasciulli A, Blundell E et al. Mycophenolate moretil as treatment of patients with acquired aplastic anaemia failing to durably respond to standard immunosuppressive treatment. Bone Marrow Transplant 2003;31 Suppl 1:0363a [abstract].
38. Scheinberg P, Nunez O, Wu C, Young N. Treatment of severe aplastic anaemia with combined immunosuppression: antithymocyte globulin, cyclosporin and mycophenolate mofetil. Br J Haematol 2006;133:606-11.
39. Brodsky R, Chen A, Brodsky I, Jones R. High-dose cyclophosphamide as salvage therapy for severe aplastic anaemia. Exp Haematol 2004;32:435-40.
40. Tisdale J, Dunn D, Geller N, Plante M, Nunez O, Dunbar C, et al. High dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet 2000;356:1554-9.
41. Lacerda J, Martins C, Carmo J, Lourenco F, Juncal C, Ismail S, et al. Haploidentical stem cell transplantation with purified CD34+ cells after a chemotherapy-alone conditioning regimen in heavily transfused severe aplastic anaemia. Biol Blood Marrow Transplant 2005;11:399-400.
42. Barker J, Weisdorf D, DeFor T, Blazar B, McGlave P, Miller J et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005;105:1343-7.
43. Mao P, Zhu Z, Wang H, Wang S, Mo W, Ying Y, et al. Sustained and stable hematopoietic donor-recipient mixed chimerism after unrelated cord blood transplantation for adult patients with severe aplastic anemia. Eur J Haematol 2005;75:430-5.
44. Fuhrer M, Baumann I, Faldum A, Niemeyer C, Janka-Schaub G, Friedrich W, et al. Immunosuppressive therapy for aplastic anaemia in children: a more severe disease predicts better survival. Blood 2005;106:2102-4.